These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 26540111)

  • 1. Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.
    Mastalerz L; Celińska-Lӧwenhoff M; Krawiec P; Batko B; Tłustochowicz W; Undas A
    PLoS One; 2015; 10(11):e0142167. PubMed ID: 26540111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered plasma fibrin clot properties in patients with digestive tract cancers: links with the increased thrombin generation.
    Gronostaj K; Richter P; Nowak W; Undas A
    Thromb Res; 2013 Mar; 131(3):262-7. PubMed ID: 23273404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased factor XI but not factor XII is associated with enhanced inflammation and impaired fibrin clot properties in patients with eosinophilic granulomatosis with polyangiitis.
    Natorska J; Ząbczyk M; Mastalerz L; Undas A
    Clin Exp Rheumatol; 2024 Apr; 42(4):822-827. PubMed ID: 38079326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.
    Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Clin Invest; 2014 Jun; 44(6):557-66. PubMed ID: 24738991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered plasma fibrin clot properties in essential thrombocythemia.
    Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
    Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
    Szczepaniak P; Zabczyk M; Undas A
    PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
    Kwasny-Krochin B; Gluszko P; Undas A
    Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
    Drabik L; Wołkow P; Undas A
    Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new insight into retinal vein occlusion pathogenesis.
    Karska-Basta I; Kubicka-Trzaska A; Pogrzebielski A; Romanowska-Dixon B
    Klin Oczna; 2013; 115(4):269-74. PubMed ID: 24908915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation.
    Celińska-Lowenhoff M; Iwaniec T; Padjas A; Musiał J; Undas A
    Thromb Haemost; 2014 Aug; 112(2):287-96. PubMed ID: 24652596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk.
    Gajos G; Konieczynska M; Zalewski J; Undas A
    Cardiovasc Diabetol; 2015 May; 14():44. PubMed ID: 25928628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
    Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
    Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
    Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
    Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome.
    Bembenek JP; Niewada M; Siudut J; Plens K; Członkowska A; Undas A
    Thromb Haemost; 2017 Jun; 117(7):1440-1447. PubMed ID: 28382369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.
    Siudut J; Grela M; Wypasek E; Plens K; Undas A
    J Thromb Haemost; 2016 Apr; 14(4):784-93. PubMed ID: 26786481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients.
    Wójcik M; Zaręba L; Undas A
    Thromb Res; 2019 Oct; 182():141-149. PubMed ID: 31479942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
    Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
    Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study.
    Cieslik J; Mrozinska S; Broniatowska E; Undas A
    Blood; 2018 Feb; 131(7):797-807. PubMed ID: 29242187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.